HomeAI · summaries
Storia in 3 fonti
Sanofi Drops Dupixent Successor Candidate After Assessing Data - Sanofi (NASDAQ:SNY)
Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety data, ending plans for regulatory filings.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Sanofi halts development of troubled immune drug in eczema
The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future blockbuster. One analyst expects Sanofi to now pursue…
- ·
endpoints.news
Sanofi nixes Kymab-originated OX40L antibody in eczema
Sanofi has decided it won’t seek an approval in atopic dermatitis for amlitelimab, the OX40-ligand antibody it had hoped would be a successor to its immunological mega-blockbuster…
